Modeling and Simulation Archives

Announcement

Certara Cuts Pharmacometrics Submission Timelines in Half: New Expedited Service Accelerates Global Regulatory Filings

Certara launches an expedited Pharmacometrics (PMx) Regulatory Submission service that cuts submission timelines in half.

CertaraDecember 3, 2025

Publication

History and Evolution of Innovations in Clinical Pharmacology

This paper reviews how decades of scientific and technological advances have transformed clinical pharmacology and…

Danielle PillsburyNovember 26, 2025

Publication

Modeling amyloid plaque turnover dynamics improves characterization of drug effects

Researchers modeled how amyloid plaques form and clear in Alzheimer’s disease, helping explain how treatments…

CertaraNovember 26, 2025

Blog

The Stepwise PIP is Here to Stay: From Pilot Flexibility to Permanent EU Regulation

The stepwise Paediatric Investigation Plan (PIP) is a strategic, flexible route for drug developers navigating…

CertaraNovember 26, 2025

Blog

Using M&S to Evaluate Oncology Drug Dosing

Learn how modeling & simulation improves oncology drug dosing, optimizing safety, efficacy, and personalized treatment…

CertaraNovember 14, 2025

Blog

ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™

At ACoP 2025, Certara showcased innovation with the launch of Certara IQ™ and Phoenix® Cloud,…

CertaraNovember 13, 2025

On-Demand Webinar

Seeing Across Species: Empiric Pharmacokinetic Time-Course Scaling in Phoenix®

Watch our on-demand webinar on empiric PK time-course scaling and learn how Certara’s translational experts…

CertaraNovember 13, 2025

Announcement

Certara Study Shows Half of Americans Unaware of FDA/NIH Move to Phase Out Animal Testing of New Drugs

Certara’s new survey findings show that 50% of Americans are unaware of FDA and NIH…

CertaraNovember 12, 2025

On-Demand Webinar

Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns

Improve pediatric drug development with Certara’s Pediatric Practice, MIDD expertise for PIPs/PSPs, dose selection, regulatory…

CertaraNovember 10, 2025

Guide

De-Risking Drug Design: How Early Feasibility Assessment Transforms Biotherapeutic Development

Learn how Early Feasibility Assessment and QSP modeling improve drug design, de-risk feasibility studies, &…

CertaraNovember 7, 2025

Modeling and Simulation

Certara Cuts Pharmacometrics Submission Timelines in Half: New Expedited Service Accelerates Global Regulatory Filings

History and Evolution of Innovations in Clinical Pharmacology

Modeling amyloid plaque turnover dynamics improves characterization of drug effects

The Stepwise PIP is Here to Stay: From Pilot Flexibility to Permanent EU Regulation

Using M&S to Evaluate Oncology Drug Dosing

ACoP 2025 Insights: Scaling the Future of QSP Modeling with Certara IQ™

Seeing Across Species: Empiric Pharmacokinetic Time-Course Scaling in Phoenix®

Certara Study Shows Half of Americans Unaware of FDA/NIH Move to Phase Out Animal Testing of New Drugs

Model-Informed Drug Development (MIDD) as a tool to Enhance Asset Value and Address Key Investor Concerns

De-Risking Drug Design: How Early Feasibility Assessment Transforms Biotherapeutic Development

Newsletter sign up

Quick links

Solutions

Contact